The World Medical Innovation Forum features CEOs of industry-leading multinational medical companies, Partners HealthCare top clinicians and scientists— all Harvard Medical School faculty members—and global technology leaders. Join 1,000 international innovation decision-makers and be briefed on the state of the art in neuroscience technology, care and research directly from the CEOs bringing game-changing products to market, world-class clinicians delivering the highest-quality care and the scientists rapidly propelling this crucial field forward through their CNS insights and discoveries. Additionally, the industry-wide issues driving investment, application and reimbursement of innovation during this period of profound transformation in healthcare will be debated.

Disruptive technologies in genomics, imaging and informatics are driving fundamental change in the American healthcare system at the same time it is being transformed from volume-based care toward one organized around value, patient outcomes and sustained health. In the neurosciences, a series of new technologies are challenging long-accepted limits of diagnosis and care while population health initiatives are changing management of chronic neurologic and psychiatric disease.

Chief executives of some of the largest and most important companies in health care, including GE, Novartis, Amgen, Biogen, Boston Scientific, Vertex and dozens of other CEOs will join Harvard clinical and research faculty—all leading physicians and scientists from Brigham and Women’s Hospital (BWH), Massachusetts General Hospital (MGH) and McLean Hospital, including Atul Gawande, MD, and Rudy Tanzi, PhD—and investors, entrepreneurs, senior government executives, corporate officers and top journalists in the Forum’s two-and-a-half-day gathering.

The inaugural World Medical Innovation Forum will be held in Boston April 27-29, 2015. Current and emerging approaches to diagnosing and caring for neurologic and psychiatric disorders will be highlighted, including multiple sclerosis, Alzheimer’s disease, Parkinson’s, depression, schizophrenia, autism, stroke and sleep disorders. Also, game-changing diagnostic tools and therapeutic interventions will be presented, including genome editing, gene therapy, neurostimulation, neuroregeneration, population management, neuroimaging and novel biomarkers.

The World Forum is organized around one clinical field per year—neurosciences in 2015 followed by cancer in 2016. The annual Forum provides attendees and policy makers with actionable insights into the torrent of new technology in the neurosciences and the swiftly evolving business of health care innovation. Attendees are senior executives of large companies, investors, entrepreneurs and officers of venture-backed companies, business-minded clinicians and investigators, government principals and dealmakers. Participants include a significant complement of international leaders and organizations.
Alzheimer’s Phoenix: New Technology, New Economics
Autism and Neurodevelopment: Are Therapies Possible Today?
Gene Editing, Gene Therapy, and the Eye as a Gateway
Gene to Drug: Kansas to Oz, Can it Happen in the Real World?
MS Transformed: Harnessing Biology and Inflammation
National Security through Neurodevelopment: Country Initiatives to Meet CNS Challenges
Neurocare, Neuromarkets, and Neuro Challenges
Neurostimulation: First-Line Therapy?
New Leaders at the Table: Filling the Gap Through Philanthropy?
Olympus Explained: Neuroinvesting from the Summit
Over the Horizon: Witnessing the Disruption of Neurocare
Parkinson’s Disease: Finally Crossing the Therapeutic Threshold
Psychiatric Targets: Finally New Mechanisms?
Regeneration, Cell Therapy, and Neurocare: Products? Delivery?
Sleep and Consciousness: Clinical Need Versus Chronic Use
Technology, Pathology, Radiology: Changing the Game Through Neurodiagnostics
The Disruptive Dozen: 12 Technologies that will Reinvent Neurocare

From start to finish
every speaker an expert, every panel unique -
an unrivaled view into CNS discovery, technologies, markets, and healthcare innovation overall
Featured Speakers

Alzheimer’s Initiative and Research Officer, Tim Coetzee, PhD
Harvard Medical School
W. Cushing Professor of Neurosurgery, Chairman, BWH Neurosurgery, Harvey Antonio Chiocca, MD, PhD
Research Affiliate, MIT
Randall Carpenter, MD
Professor of Anaesthesia, CEO, Amgen
CEO, Editas Medicine
Katrine Bosley
CEO, Extreme Medicine
Robert Bradway
CEO, Amgen
David Brennan
CEO, AstraZeneca (Ret.)

Emery Brown, MD, PhD
MGH Anaesthesia, Warren M. Zapol Professor of Anaesthesia, Harvard Medical School
Randall Carpenter, MD
Research Affiliate, MIT
Antonio Chiocca, MD, PhD
Chairman, MGH Neuroangiography, James Dom Professor of Neurosurgery, Harvard Medical School
Mark Coetzee, PhD
Mass Analytic and Translational Genetics, Associate Professor of Medicine, Harvard Medical School

Mark Dalry, PhD
Mass Analytic and Translational Genetics, Associate Professor of Medicine, Harvard Medical School

Mark Demitrack, MD
CMO, Neuromics
Richard Dumitrescu, PhD
Global Head of Neurosciences, Neurosciences Institute for Biomedical Research
Dawnette Dusinberre, MD
CEO, Forum Pharmaceuticals
Michael Ehlers, MD, PhD
Neuroscience CSO, Pfizer
Emad Eskandar, MD
MGH Neurosurgery, Charles Pappas Professor of Neurosurgery, Harvard Medical School
Maurizio Fava, MD
Executive Vice Chair, MGH Psychiatry, Professor of Psychiatry, Harvard Medical School
Frank Fisher
CEO, Neurotech
Mark Fishman, MD
Gouverneur: Novartis Institutes for BioMedical Research (NIBR)
Peter Ford
Founder and CEO, Control Biosciences
Jean-François Formela, MD
Partner, Akeo Ventures

Pete Frates
Champion, ALS Ice Bucket Challenge
Sancary Frates
The Pete Frates $3 Fund
Atul Gawande, MD
BWH Surgery, Professor of Surgery, Harvard Medical School
Gideon Gill
Science Editor, The Boston Globe
Alexandra Golly, MD
BWH Medicine and Neurology, Baldini Professor of Sleep Medicine, Harvard Medical School

David Altschuler, MD, PhD
MGH Molecular Biology, MGH Neurology, Frank and Maureen of Radiology, Harvard Medical School
Brad Hyman, MD, PhD
CSO, McLean Hospital, Managing Partner, High Lantern
Leonard H. Fisher, MD
Chairman, BWH Pathology, Professor of Pathology, Harvard Medical School

Frank Fischer
CEO, Neurotech
Mark Fishman
Gouverneur: Novartis Institutes for BioMedical Research (NIBR)
Peter Ford
Founder and CEO, Control Biosciences
Jean-François Formela, MD
Partner, Akeo Ventures

Peter Frates
Champion, ALS Ice Bucket Challenge
Sancary Frates
The Pete Frates $3 Fund
Atul Gawande, MD
BWH Surgery, Professor of Surgery, Harvard Medical School
Gideon Gill
Science Editor, The Boston Globe
Alexandra Golly, MD
BWH Medicine and Neurology, Baldini Professor of Sleep Medicine, Harvard Medical School
Jeffrey Golden, MD
Chairman, BWH Pathology, Ramey S. Coton Professor of Pathology, Harvard Medical School
Corey Goodman, PhD
Managing Partner, Junto
Gary Gottlieb, MD
CEO, Partners HealthCare, Professor of Psychiatry, Harvard Medical School
Phillip Gregory, D. Phil, Senior Vice President and CSO, Sarepta Biotechnologies
Rich Gregory, PhD
Head of Genzyme R&D Center
Jeffery Gucler, MD, PhD
President, CNSO, NOVOCIDE Health
Sean Harper, MD, PhD
Executive Vice President, Research and Development, Amgen

Martin McCance
Chairman Emeritus, Greepack Partners
Henry McNamee
Chairman Emeritus, Greepack Partners
Christopher McDougle, MD
Director, Larive Center for Autism, MGH for Children’s Autism, Assistant Professor of Psychiatry, Harvard Medical School
Martin McClynn
CEO, Status Genetics
Michael Meeker, MD
President, CEO, Genzyme
Doug Melton, PhD
Sara University Professor, Harvard, Howard Hughes Medical Institute Professor, Department of Stem Cell and Regenerative Biology
Gregg Meyer, MD
Chief Clinical Officer, Partners HealthCare
Matt Miller
Host, NPR
Brad Hymann, MD, PhD
MGH Neurology, John R. Penny Jr. Professor of Neurology, Harvard Medical School
Jim Insel
CEO, General Electric

Ole Isacson, MD
McLean Neuroregenerative Research, Professor of Neurology, Harvard Medical School
Joe Jimenez
CEO, Novartis
Kaiju Kaul
Senior National Correspondent, Fox News

Annie Romney
Global Ambassador, Amyotrophic Lateral Sclerosis Association
Bruce Rosen, MD, PhD
MGH Neurology, Professor of Radiology, Harvard Medical School

David Moeller
CEO, Vertex Pharmaceuticals

Bill Shalaby
Simon, V. D’Arbelof - MBA Class of 1955

John Roberts
Senior National Correspondent, Fox News

Ann Romney
Global Ambassador, Amyotrophic Lateral Sclerosis Association
Bruce Rosen, MD, PhD
MGH Neurology, Professor of Radiology, Harvard Medical School

Scott Rauch, MD
Senior National Correspondent, Fox News

Karl De Smedt, MD
CEO, Biogen Idec

George Scangos, PhD
CEO, Biogen Idec
Dale Sheink, PhD
CEO, Previta
Clemens Schaefer, MD
Biomedical Neurology, Associate Professor of Neurology, Harvard Medical School

Michael Schwartzschild, MD, PhD
MGH Neurology, Professor of Neurology, Harvard Medical School

Danny Selsor, MD
BWH Neurology, Vincent and Stella Castets Professor of Neurologic Diseases, Harvard Medical School

Todd Sherrer, PhD
CEO, The Michael J. Fox Foundation for Parkinson’s Research

Sue Sigel
CEO, Universities and healthphysiography

David Silbersweig, MD
Chairman, BWH Psychiatry, Stanley Cobb Professor of Psychiatry, Harvard Medical School

Monsu Slaoui, PhD
President, GlaxoSmithKline

Peter Slavin, MD
President, MGH, Professor of Healthcare Policy, Harvard Medical School

Nancy Snyderman, MD
Chief Medical Editor, NBC News

Rudy Tanzi, PhD
MGH Neurology, Joseph P. and Rose F. Kennedy Professor of Child Neurology and Mental Retardation, Massachusetts General Hospital

Meg Tullar
Biotech & Pharma Reporter, CNBC

Steven Tregay
CFO, FormFactor Therapeutics

Ajay Verma, MD, PhD
VP, Experimental Medicine, Biogen Idec

Jeff Walker
Vice Chair, United Nations Entity’s Office for Health Finance and Malnutrition

Howard Weiner, MD
Chairman, Partners HealthCare Multiple Sclerosis Center, Robert Harris Professor of Neurology, Harvard Medical School

* Additional Speakers Being Confirmed

Diane Saper, PhD
CEO, Previta

Clemens Schaefer, MD
Biomedical Neurology, Associate Professor of Neurology, Harvard Medical School

Michael Schwartzschild, MD, PhD
MGH Neurology, Professor of Neurology, Harvard Medical School

Danny Selsor, MD
BWH Neurology, Vincent and Stella Castets Professor of Neurologic Diseases, Harvard Medical School

Todd Sherrer, PhD
CEO, The Michael J. Fox Foundation for Parkinson’s Research

Sue Sigel
CEO, Universities and healthphysiography

David Silbersweig, MD
Chairman, BWH Psychiatry, Stanley Cobb Professor of Psychiatry, Harvard Medical School

Monsu Slaoui, PhD
President, GlaxoSmithKline

Peter Slavin, MD
President, MGH, Professor of Healthcare Policy, Harvard Medical School

Nancy Snyderman, MD
Chief Medical Editor, NBC News

Rudy Tanzi, PhD
MGH Neurology, Joseph P. and Rose F. Kennedy Professor of Child Neurology and Mental Retardation, Massachusetts General Hospital

Meg Tullar
Biotech & Pharma Reporter, CNBC

Steven Tregay
CFO, FormFactor Therapeutics

Ajay Verma, MD, PhD
VP, Experimental Medicine, Biogen Idec

Jeff Walker
Vice Chair, United Nations Entity’s Office for Health Finance and Malnutrition

Howard Weiner, MD
Chairman, Partners HealthCare Multiple Sclerosis Center, Robert Harris Professor of Neurology, Harvard Medical School

* Additional Speakers Being Confirmed
Join Us for the 2015 World Medical Innovation Forum

Experience the state of the art in neuroscience technology, care and research

Understand the prospects for innovation in a transformed health care industry

See firsthand the breakthrough neuro technologies from across the industry

Forge relationships and exchange information with world-recognized clinicians, investors, entrepreneurs, scientists, CEOs, executives, government leaders, philanthropists, and journalists

BROUGHT TO YOU BY:

101 Huntington Avenue, 4th Floor   |   Boston, MA 02199
617-954-9500   |   innovation.partners.org

BROUGHT TO YOU BY:

101 Huntington Avenue, 4th Floor   |   Boston, MA 02199
617-954-9500   |   innovation.partners.org